A carregar...
Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis
OBJECTIVE: Originator intravenous rituximab is an important rheumatology treatment but is costly, and administration requires several hours. Because biosimilar rituximab may cost less and subcutaneous rituximab requires a shorter visit, both may reduce costs and increase treatment capacity (infusion...
Na minha lista:
| Publicado no: | ACR Open Rheumatol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7231514/ https://ncbi.nlm.nih.gov/pubmed/32314553 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr2.11133 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|